nach oben

Erschienen in:

17.07.2021 | Nephrology - Review

Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis

verfasst von: Mehmet Kanbay, Laura Tapoi, Carina Ureche, Cem Tanriover, Enes Cevik, Atalay Demiray, Baris Afsar, David Z. I. Cherney, Adrian Covic

Erschienen in: International Urology and Nephrology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Sodium–glucose cotransporter 2 inhibitors (SGLT2i) improve outcomes of patients with type 2 diabetes at high cardiovascular risk and chronic kidney disease. Recent studies showed an increase in hemoglobin and hematocrit after SGLT2i treatment.

Materials and methods

We did a systematic review and meta-analysis of randomized, double-blind, placebo-controlled studies of SGLT2i in patients with type 2 diabetes. We searched through PubMed/Medline, Web of Science, Embase (Elsevier), and the Cochrane Central Register of Controlled Trials (Wiley) from January 2010 to January 2021.

Results

We included seventeen randomized, double-blind, placebo-controlled studies. The total number of evaluated patients was 14,748. The treatment arm consisted of canagliflozin, dapagliflozin, empagliflozin and ipragliflozin. SGLT2i therapy significantly increased hemoglobin levels when compared to placebo (MD 5.60 g/L, 95% CI 3.73–7.47 g/L, P < 0.00001, considerable heterogeneity—I² = 94%). Each SGLT2i also led to a significant increase in the hematocrit level when compared to placebo (MD 1.32%, 95% CI 1.21–1.44, P < 0.00001, considerable heterogeneity—I² = 99%).

Conclusions

SGLT2i led to significant increases in hemoglobin and hematocrit levels when compared to placebo. In addition to their cardiovascular effect, SGLT2i also increases hemoglobin and hematocrit levels.

Nur mit Berechtigung zugänglich

Cherney DZ, Kanbay M, Lovshin JA (2020) Renal physiology of glucose handling and therapeutic implications. Nephrol Dial Transplant 35:i3–i12CrossRef

Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-Gonzalez JF, Soler MJ, Gorriz JL, Ortiz A (2020) SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J 13:728–733CrossRef

Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A, Covic A, Kuwabara M, Cherney DZI, van Raalte DH, de Zeeuw D (2019) Renal hyperfiltration defined by high estimated glomerular filtration rate: a risk factor for cardiovascular disease and mortality. Diabetes Obes Metab 21:2368–2383CrossRef

Yilmaz MI, Solak Y, Covic A, Goldsmith D, Kanbay M (2011) Renal anemia of inflammation: the name is self-explanatory. Blood Purif 32:220–225CrossRef

Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A (2010) Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management. Blood Purif 29:1–12CrossRef

Solak Y, Cetiner M, Siriopol D, Tarim K, Afsar B, Covic A, Kanbay M (2016) Novel masters of erythropoiesis: hypoxia inducible factors and recent advances in anemia of renal disease. Blood Purif 42:160–167CrossRef

Copur S, Onal EM, Afsar B, Ortiz A, van Raalte DH, Cherney DZ, Rossing P, Kanbay M (2020) Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality. J Diabetes Complicat 34:107707CrossRef

Maruyama T, Takashima H, Oguma H, Nakamura Y, Ohno M, Utsunomiya K, Furukawa T, Tei R, Abe M (2019) Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease. Diabetes Technol Ther 21:713–720CrossRef

Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, investigators E-RPt (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158CrossRef

10.

List JF, Woo V, Morales E, Tang W, Fiedorek FT (2009) Sodium–glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32:650–657CrossRef

11.

Bailey CJ, Iqbal N, T’Joen C, List JF (2012) Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14:951–959CrossRef

12.

O’Neill J, Fasching A, Pihl L, Patinha D, Franzen S, Palm F (2015) Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats. Am J Physiol Renal Physiol 309:F227-234CrossRef

13.

Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W, Canagliflozin DIASG (2012) Dose-ranging effects of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35:1232–1238CrossRef

14.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRef

15.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRef

16.

Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (eds) (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley, Chichester

17.

DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105–114CrossRef

18.

Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC, Investigators E-RMT (2013) Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 36:3396–3404CrossRef

19.

Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928–938CrossRef

20.

Bailey CJ, Gross JL, Pieters A, Bastien A, List JF (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223–2233CrossRef

21.

Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, Parikh S (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97:1020–1031CrossRef

22.

Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K (1995) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013(41):72–84

23.

Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF (2010) Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33:2217–2224CrossRef

24.

Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, Tokudome T, Langkilde AM, Parikh S (2013) Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15:432–440CrossRef

25.

Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56:2582–2592CrossRef

26.

Rosenstock J, Vico M, Wei L, Salsali A, List JF (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473–1478CrossRef

27.

Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, Canovatchel W, Meininger G (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15:372–382CrossRef

28.

Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A (2013) Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab 15:403–409CrossRef

29.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S, Dapagliflozin 006 Study G (2012) Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 156:405–415CrossRef

30.

Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15:463–473CrossRef

31.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128CrossRef

32.

Rangaswami J, Bhalla V, de Boer IH, Staruschenko A, Sharp JA, Singh RR, Lo KB, Tuttle K, Vaduganathan M, Ventura H, McCullough PA, American Heart Association Council on the Kidney in Cardiovascular D, Council on Arteriosclerosis T, Vascular B, Council on C, Stroke N, Council on Clinical C, Council on L, Cardiometabolic H (2020) Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation 142:e265–e286CrossRef

33.

Yerlikaya A, Bulbul MC, Afsar B, Dagel T, Aslan G, Voroneanu L, Siriopol D, Covic A, Kanbay M (2018) Iron in kidney and heart failure: from theory to practice. Int Urol Nephrol 50:481–493CrossRef

34.

Afsar B, Kanbay M, Afsar RE (2020) Hypoxia inducible factor-1 protects against COVID-19: a hypothesis. Med Hypotheses 143:109857CrossRef

35.

Lawler PR, Liu H, Frankfurter C, Lovblom LE, Lytvyn Y, Burger D, Burns KD, Brinc D, Cherney DZI (2021) Changes in cardiovascular biomarkers associated with the sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin in patients with chronic kidney disease and type 2 diabetes. Diabetes Care 2021 Mar;44(3):e45-e47. https://doi.org/10.2337/dc20-2265CrossRefPubMed

36.

Packer M (2020) Mutual antagonism of hypoxia-inducible factor isoforms in cardiac, vascular, and renal disorders.JACC Basic Transl Sci 5:961–968CrossRef

37.

Bessho R, Takiyama Y, Takiyama T, Kitsunai H, Takeda Y, Sakagami H, Ota T (2019) Hypoxia-inducible factor-1alpha is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep 9:14754CrossRef

38.

Ghanim H, Abuaysheh S, Hejna J, Green K, Batra M, Makdissi A, Chaudhuri A, Dandona P (2020) Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020 Apr 1; 105(4):dgaa057CrossRef

39.

Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J (2013) Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 15:853–862CrossRef

40.

Afsar B, Hornum M, Afsar RE, Ertuglu LA, Ortiz A, Covic A, van Raalte DH, Cherney DZI, Kanbay M (2021) Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion 58:72–82CrossRef

Titel: Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis
verfasst von: Mehmet Kanbay
Laura Tapoi
Carina Ureche
Cem Tanriover
Enes Cevik
Atalay Demiray
Baris Afsar
David Z. I. Cherney
Adrian Covic
Publikationsdatum: 17.07.2021
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 4/2022
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-021-02943-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis